Curis, Inc. (CRIS): Price and Financial Metrics

Curis, Inc. (CRIS): $0.72

-0.01 (-1.17%)

POWR Rating

Component Grades













Add CRIS to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where CRIS ranks best; there it ranks ahead of 64.02% of US stocks.
  • The strongest trend for CRIS is in Stability, which has been heading down over the past 179 days.
  • CRIS's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

CRIS Stock Summary

  • With a price/sales ratio of 21.43, Curis Inc has a higher such ratio than 93.37% of stocks in our set.
  • With a year-over-year growth in debt of -34.22%, Curis Inc's debt growth rate surpasses only 11.91% of about US stocks.
  • In terms of volatility of its share price, CRIS is more volatile than 91.07% of stocks we're observing.
  • Stocks that are quantitatively similar to CRIS, based on their financial statements, market capitalization, and price volatility, are VYGR, AGLE, FUSN, MCRB, and CHRS.
  • Visit CRIS's SEC page to see the company's official filings. To visit the company's web site, go to

CRIS Valuation Summary

  • In comparison to the median Healthcare stock, CRIS's price/sales ratio is 597.8% higher, now standing at 79.2.
  • CRIS's price/sales ratio has moved down 161 over the prior 243 months.
  • CRIS's EV/EBIT ratio has moved down 21.2 over the prior 243 months.

Below are key valuation metrics over time for CRIS.

Stock Date P/S P/B P/E EV/EBIT
CRIS 2021-08-31 79.2 7.2 -23.7 -21.6
CRIS 2021-08-30 76.2 6.9 -22.8 -20.7
CRIS 2021-08-27 74.8 6.8 -22.4 -20.3
CRIS 2021-08-26 71.3 6.5 -21.3 -19.3
CRIS 2021-08-25 71.9 6.5 -21.5 -19.5
CRIS 2021-08-24 70.7 6.4 -21.1 -19.1

CRIS Growth Metrics

    The year over year price growth rate now stands at 1757.31%.
  • Its 2 year net income to common stockholders growth rate is now at 33.85%.
  • The 2 year cash and equivalents growth rate now stands at -45.42%.
CRIS's revenue has moved up $922,000 over the prior 34 months.

The table below shows CRIS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 10.649 -37.619 -45.436
2021-09-30 10.538 -35.163 -39.333
2021-06-30 10.241 -31.43 -34.256
2021-03-31 10.315 -29.902 -30.126
2020-12-31 10.835 -25.739 -29.908
2020-09-30 11.098 -25.623 -30.999

CRIS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRIS has a Quality Grade of C, ranking ahead of 36.2% of graded US stocks.
  • CRIS's asset turnover comes in at 0.066 -- ranking 302nd of 682 Pharmaceutical Products stocks.
  • YMTX, VTRS, and KDNY are the stocks whose asset turnover ratios are most correlated with CRIS.

The table below shows CRIS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.066 0.950 -0.571
2021-03-31 0.085 0.950 -0.771
2020-12-31 0.135 0.951 -1.416
2020-09-30 0.291 0.951 -5.061
2020-06-30 0.301 0.951 -6.257
2020-03-31 0.287 0.952 -7.307

CRIS Price Target

For more insight on analysts targets of CRIS, see our CRIS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.00 Average Broker Recommendation 1.5 (Moderate Buy)

CRIS Stock Price Chart Interactive Chart >

Price chart for CRIS

CRIS Price/Volume Stats

Current price $0.72 52-week high $15.60
Prev. close $0.73 52-week low $0.70
Day low $0.70 Volume 1,768,600
Day high $0.76 Avg. volume 2,235,996
50-day MA $1.37 Dividend yield N/A
200-day MA $4.49 Market Cap 65.98M

Curis, Inc. (CRIS) Company Bio

Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.

CRIS Latest News Stream

Event/Time News Detail
Loading, please wait...

CRIS Latest Social Stream

Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis Inc. (CRIS) CEO James Dentzer on Q4 2021 Results - Earnings Call Transcript

Curis Inc. (CRIS) Q4 2021 Earnings Conference Call February 24, 2022, 4:30 PM ET Company Participants James Dentzer – President & Chief Executive Officer Bill Steinkrauss – Chief Financial Officer & Chief Administrative Officer Bob Martell – Head of R&D Conference Call Participants Alethia Young – Cantor Fitzgerald Edward White...

SA Transcripts on Seeking Alpha | February 25, 2022

Curis (CRIS) Q4 2021 Earnings Call Transcript

Thank you, and welcome to Curis' fourth quarter and year-end 2021 [Audio gap] Before we begin, I would encourage everyone to go to the investors section of our website at to find our fourth quarter and year-end 2021 and earnings release and related financial tables. For additional details, please see our SEC filings.

Yahoo | February 25, 2022

Curis (CRIS) Reports Q4 Loss, Tops Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of -15.38% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Curis Reports Fourth Quarter and Year End 2021 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter ended December 31, 2021.

Yahoo | February 24, 2022

Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022

No summary available.

investors Curis | February 17, 2022

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo -26.51%
3-mo -77.50%
6-mo -85.12%
1-year -95.00%
3-year -48.20%
5-year -91.63%
YTD -84.87%
2021 -41.88%
2020 381.76%
2019 146.38%
2018 -80.29%
2017 -77.27%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5945 seconds.